Showing results (151-160 of 159) with videos related to
Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 159 results.
Journal of the American Academy of Dermatology|April 26, 2025
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trialAndrew Blauvelt, Richard G Langley, Mark Lebwohl, et al.Lancet (London, England)|August 12, 2018
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsKenneth B Gordon, Bruce Strober, Mark Lebwohl, et al.JAMA Dermatology|May 15, 2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical TrialMark Lebwohl, Andrew Blauvelt, Cynthia E Kartman, et al.Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.Plos One|January 23, 2026
Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasisRichard B Warren, Hamish J A Hunter, Kim A Papp, et al.Journal of the American Academy of Dermatology|November 6, 2007
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl, Jerry Bagel, Joel M Gelfand, et al.Dermatology and Therapy|December 23, 2018
Clinical Goals and Barriers to Effective Psoriasis CareBruce E Strober, Joelle M van der Walt, April W Armstrong, et al.Journal of the American Academy of Dermatology|December 3, 2016
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasisApril W Armstrong, Michael P Siegel, Jerry Bagel, et al.Pageof 16